Initiation of menopausal hormone therapy among perimenopausal and recently postmenopausal women with vasomotor symptoms is associated with a 22% reduction in cardiovascular events, according to a target trial emulation published in JAMA Internal Medicine. Researchers led by Samar El Khoudary of the Virginia Commonwealth University School of Public Health found the cardiovascular benefit was concentrated in women who started treatment within 10 years of menopause onset and in Black women, though the authors cautioned against using the therapy solely for heart disease prevention.
Timing and Demographics Shape Cardiovascular Findings
According to the JAMA Internal Medicine study, women who initiated menopausal hormone therapy within 10 years of menopause onset experienced an estimated 27% reduction in cardiovascular disease risk (adjusted HR 0.73). However, researchers observed no such benefit when hormone therapy was initiated more than 10 years after menopause onset (adjusted HR 1.53). Race also influenced outcomes, with treatment indicating a protective effect specifically for Black women (adjusted HR 0.51), while showing no clear benefit for other races, according to El Khoudary and co-authors.
Pro Tip: Discussing the exact timeline of your menopause transition with a healthcare provider is critical before starting hormone therapy, as the window within 10 years of onset appears to carry distinct protective cardiovascular associations not seen later in life.
Contrasting Biomarker Data From Clinical Analyses
While the observational target trial emulation tracked clinical cardiovascular events over a 20-year period using data from the Study of Women’s Health Across the Nation (SWAN), a separate analysis published in Obstetrics & Gynecology examined specific biomarkers to understand how these therapies affect cholesterol and blood lipids. According to the Obstetrics & Gynecology study analyzing Women’s Health Initiative data, women taking oral estrogen or combination estrogen-progesterone experienced an 11% drop in LDL (“bad”) cholesterol and a 13% increase in HDL (“good”) cholesterol in the estrogen-only group.
Risk-Benefit Balance and Regulatory Shifts
Despite these observed biomarker improvements and cardiovascular associations, study authors emphasized that the overall risk-benefit balance means menopausal hormone therapy should not be prescribed primarily for cardiovascular prevention. El Khoudary noted that the study observed an increased breast cancer risk among initiators compared with non-initiators (adjusted HR 1.41), while venous thromboembolism events showed no significant difference between the groups. This research arrives shortly after the FDA approved label changes for six hormone replacement therapies to remove boxed warnings regarding cardiovascular disease, breast cancer, and probable dementia—warnings that had been in place for over two decades following the pivotal Women’s Health Initiative trial, as reported by MedPage Today.
Expert Perspectives on Formulation Differences
In an accompanying commentary in JAMA Internal Medicine, Regina Castaneda and Stephanie Faubion of the Mayo Clinic in Jacksonville, Florida, pointed out that the cardiovascular effects of hormone therapy during the early stages of the transition remain poorly characterized. They noted that the existing evidence is limited by the wide variety of hormone preparations and delivery routes used across studies, such as systemic oral or transdermal estrogen with or without progestogens, including oral contraceptives. Castaneda and Faubion stated that these formulations, particularly those in contraceptives featuring higher doses and synthetic progestins, differ meaningfully from standard postmenopausal regimens and warrant careful clinical discussion.
Frequently Asked Questions
Does menopausal hormone therapy prevent heart disease?
No. According to the study authors, menopausal hormone therapy should not be used for cardiovascular prevention, despite observational data showing a 22% reduction in cardiovascular events among specific younger and recently postmenopausal cohorts.
When is the safest time to start menopausal hormone therapy?
What are the primary risks associated with menopausal hormone therapy?
Clinical data indicate an increased risk of breast cancer among initiators, alongside potential increases in triglycerides and blood-clotting proteins, which require careful individual risk assessment with a healthcare provider.
Stay Informed on Women’s Health Research
Subscribe to our newsletter to receive the latest peer-reviewed findings, expert medical commentary, and breaking health policy updates directly in your inbox.
Subscribe Now